EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Advances in Research on COVID-19 Vaccination for People Living with HIV

Junyan Jin, Xiuwen Wang, Raphael Carapito, Christiane Moog, Bin Su

Infectious Diseases & Immunity · 2022

DOI: 10.1097/id9.0000000000000065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infectious Diseases & Immunity, 2022. Verfasst von Junyan Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Res…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction In December 2019, multiple cases of aggravated pneumonia of unidentified origin were reported in Wuhan, China. These were confirmed to be caused by a novel coronavirus. The World Health Organization (WHO) named the disease coronavirus disease 2019 (COVID-19). The International Committee on Taxonomy of Viruses officially identified the novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[1] Although China is now a low endemic area with a downward trend in the number of confirmed and suspected cases,[2] the threat of the COVID-19 pandemic remains critical. By mid-March 2022, the cumulative number of reported confirmed cases of COVID-19 worldwide exceeded 450 million, with more than 6 million deaths.[3] Since there is no specific therapeutic drug for the treatment of COVID-19, it is important to control the epidemic by actively promoting SARS-CoV-2 vaccination globally, reducing the risk of viral transmission and the incidence of severe COVID-19, thus improving prognoses.[4] The human immunodeficiency virus (HIV) pandemic has resulted in nearly 37.7 million people being infected with HIV worldwide. People living with HIV (PLWH) are classified by the WHO as imposing a higher peril for SARS-CoV-2 infection. Although HIV infection is not a risk factor for COVID-19, several studies have shown that the clinical course of PLWH, especially for those with low CD4+ T cell counts and untreated HIV infection, may be more severe than that in HIV-negative populations.[5–9] PLWH are typically excluded from randomized clinical trials of antiviral drugs, immunomodulators, and vaccines, resulting in the lack of large-scale safety and efficacy data to support COVID-19 vaccination strategies in this population.[10] This study reviewed the current data and challenges of COVID-19 vaccination among PLWH, summarizing their willingness to receive the vaccination and the factors that influence this decision to receive the COVID-19 vaccine and providing a reference for subsequent studies. Intentions and factors influencing the decision for COVID-19 vaccination in PLWH There are few data on the willingness of PLWH to receive COVID-19 vaccination. A single-center online survey among PLWH who had been vaccinated against SARS-CoV-2 in France showed that 28.7% (68/237) of participants expressed hesitation.[11] Another online survey study, including 1942 healthy individuals on their inclination on receiving the COVID-19 vaccine, demonstrated that approximately 28.8% of the participants outright refused to be vaccinated.[12] However, a study analyzed the uptake of the COVID-19 vaccine in 44,260 individuals, with 15 survey samples from 10 low- and middle-income countries in Asia, Africa, South America, Russia (an upper-middle-income country), and the United States, and found that the intention to receive the COVID-19 vaccine was high, with a mean of up to 80.3%.[13] Another US online survey of PLWH regarding COVID-19 vaccination showed that 319 of the 496 individuals had received at least one dose of the COVID-19 vaccine, and 66.3% of those who had not received at least one dose of the COVID-19 vaccine at the time of the survey said they would receive the vaccine when it became available to them.[14] A Chinese study, using an online questionnaire that recruited 527 PLWH who had received the COVID-19 vaccine and 1091 unvaccinated PLWH, showed high rates of inclination to receive the COVID-19 vaccine among individuals with higher levels of education and those with occupations with a higher risk of novel coronavirus infection, such as essential urban security workers, international transport workers, quarantine entry point workers, and cold chain logistics workers.[15] According to this study, fear of adverse effects was the most common concern for hesitation.[13] Adverse reactions to COVID-19 vaccination in PLWH include negative impacts on HIV/AIDS disease progression or antiretroviral therapy (ART), disclosure of HIV infection status, or underlying comorbidities.[14–16] The percentage of PLWH undergoing COVID-19 vaccination also varies by sex, race, sexual orientation, CD4+ T cell count, viral load, and education, with one study showing that men infected with COVID-19 were five times more likely than women to receive the vaccine.[17] A study including 6441 PLWH showed that individuals with CD4+ T cell counts >200 cells/μL were more likely to be vaccinated with the COVID-19 vaccine than those with CD4+ T cell counts 500 cells/μL had higher seroconversion rates, neutralizing antibody positivity, and functional activity.[69] These results suggest that vaccine-induced antibody responses are dependent on CD4+ T cells. Development of humoral and cellular immune responses to inactivated SARS-CoV-2 vaccines may take longer in PLWH. Further follow-up of the immune response is needed to determine how inactivated SARS-CoV-2 vaccines respond to PLWH. Adverse reactions to vaccination in PLWH Current studies have shown that most COVID-19 vaccines are safe and well-tolerated in PLWH. The adverse reactions to COVID-19 vaccination are mild in PLWH, with injection site pain being the most common adverse reaction, followed by fatigue, headache, dizziness, or drowsiness.[15,54,55,70] In the evaluation of the efficacy and safety of the BNT162b2 mRNA vaccine in immunodeficient populations, including HIV-infected individuals, the rates of reported adverse events between immunodeficient populations and healthy controls were not significantly different. Interestingly, the incidence of systemic reactions (fever, chills, headache, tiredness/fatigue, diarrhea, vomiting, new/worsened muscle pain, or joint pain) was slightly lower in PLWH than that in healthy controls after two doses of the mRNA vaccine. These decreased adverse effects may be related to the immunosuppressed state of the PLWH.[71] For vaccination with inactivated virus, the overall incidence of adverse events within 7 days was similar between PLWH and healthy controls.[67] Currently, inactivated vaccines do not induce serious adverse events in PLWH. Indeed, the proportion of adverse reactions in PLWH inoculated with inactivated vaccines was significantly lower than that in PLWH that received mRNA vaccines.[42] However, more targeted studies with larger sample sizes are required. Conclusion and outlook The COVID-19 pandemic continues to ravage the world, and different types of vaccines have been designed and developed in several countries worldwide. The design of COVID-19 vaccines requires eliciting broad humoral, cellular, and mucosal immune responses to effectively reduce transmission and severe disease. Several studies have shown that mRNA vaccines have superior immunogenicity compared with vector and inactivated vaccines in healthy controls.[72] Moreover, studies have demonstrated that the immune response is stronger in HIV-negative individuals when applying the mRNA-1273 vaccine (Moderna) compared with BNT162b2 (Pfizer-BioNTech) because of its higher mRNA content and longer interval (4 vs. 3 weeks) in healthy controls[46] as well as in PLWH.[38,48,49] Vaccine effectiveness (VE) against COVID-19 hospitalizations was higher for the Moderna vaccine than for the Pfizer-BioNTech vaccine, and VE for both mRNA vaccines was higher than that for the Janssen vaccine.[72] However, it is still not clear which COVID-19 vaccine produces the best safety and protection. COVID-19 mRNA vaccines represent a new class of vaccines. Therefore, it is difficult to directly compare the seroconversion rates of COVID-19 mRNA vaccines with those of traditional and frequently used vaccines. Owing to their compromised immune status, vaccine-induced immune responses might be impaired in PLWH, which affects various immunological pathways causing immune activation, impaired cellular and humoral responses, and their clinical outcomes.[68] However, a systematic review and meta-analysis evaluating the safety and efficacy of COVID-19 vaccination in immunocompromised populations showed that mRNA vaccines appeared to be the most effective after two doses compared with non-replicating viral vector vaccines and inactivated vaccines.[31] This is similar to recent results comparing the safety and efficacy of different types of vaccines in immunocompetent populations.[73,74] Additional vaccination studies involving PLWH with COVID-19 are necessary for the future to gain further insight into the persistence of humoral and cellular immunity to SARS-CoV-2.[75] If SARS-CoV-2 undergoes a large degree of mutation, the vaccines under development may no longer work for the mutated virus. It is yet to discover what level of immunity is required to prevent hospitalization and death, but real-world data suggest that vaccination is successful in preventing these even in the presence of transmissible and virulent variants of concern (VOCs).[56,76] In the future, repeated boosting might be necessary to maintain long-term immunological memory of SARS-CoV-2 and VOCs, especially for immunocompromised populations such as PLWH. Therefore, there is a need to increase the surveillance of the virus so that effective measures can be taken promptly. Moreover, to improve the immune efficacy and duration of SARS-CoV-2 vaccination, different vaccine types should be tested in combination. A heterologous mRNA booster after two doses of inactivated vaccine elicited higher levels of neutralizing antibodies than the inactivated vaccine alone.[77] A recent study showed that the mRNA BNT162b2 and inactivated CoronaVac vaccines had higher VE for BNT162b2 after one and two doses, but similar performance after three doses.[78] Further research is needed on PLWH receiving different types of COVID-19 vaccines. Both inactivated whole-virus vaccines and mRNA vaccines or adenovirus vector vaccines provide sufficient protection against severe COVID-19, and vaccination remains a key strategy against the disease. As PLWH are among the most vulnerable populations, vaccination coverage for these people should be prioritized. Antibodies produced by PLWH may decay more rapidly than those produced by the uninfected population. Therefore, additional boosting may be proposed to achieve antibody levels necessary for protection in PLWH. Moreover, further vaccine efficacy studies in PLWH should be performed to elucidate the potential impact of various immunization strategies, according to their disease status and outcome.

Schlagwörter

Stichwörter der Autor:innen

COVID-19HIVPLWHSARS-CoV-2Vaccination

Autor:innen und Institutionen

  • Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital…
  • Laboratoire d'ImmunoRhumatologie Moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR_S 1109, Institut Thématique Interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplan…

Zitieren

APA

Jin, J., Wang, X., Carapito, R., Moog, C., & Su, B. (2022). Advances in Research on COVID-19 Vaccination for People Living with HIV. Infectious Diseases & Immunity. https://doi.org/10.1097/id9.0000000000000065

Vancouver

Jin J, Wang X, Carapito R, Moog C, Su B. Advances in Research on COVID-19 Vaccination for People Living with HIV. Infectious Diseases & Immunity. 2022. doi:10.1097/id9.0000000000000065

BibTeX
@article{Jin2022,
  author = {Jin, Junyan and Wang, Xiuwen and Carapito, Raphael and Moog, Christiane and Su, Bin},
  title = {Advances in Research on COVID-19 Vaccination for People Living with HIV},
  journal = {Infectious Diseases & Immunity},
  year = {2022},
  doi = {10.1097/id9.0000000000000065}
}
Kostenlos starten →